To read the full story, subscribe or sign in.

Medivation Rocked by Dimebon Miss in Late-Stage AD Study

March 4, 2010

Shares in Medivation Inc. fell 67.5 percent Wednesday on news that its Phase III trials of Alzheimer's drug candidate Dimebon missed all of the study's stated goals, smashing some high hopes on Wall Street. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Jan 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 5, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...